SREA
SEMPRA
$21.07
-1.08%
$13.5B
No data for this timeframe.
Vol
Market Cap$13.5B
Cap SizeLarge Cap
SEC Reports5
Recent Activity
Jun 4, 2026
SEC
Sempra filed a preliminary prospectus supplement for an offering of Floating Rate Notes due 2028, with the aggregate pri
424B5 — Impact 4/10
May 15, 2026
SEC
Southern California Gas Company (an indirect subsidiary of Sempra) closed the public offering of $650 million aggregate
8-K — Impact 3/10
May 14, 2026
SEC
Sempra officer Diana L. Day filed a Form 144 to sell 3,300 shares of common stock with an estimated aggregate market val
144 — Impact 2/10
Analyst Ratings
6Strong Buy
12Buy
6Hold
0Sell
0Strong Sell
Latest Reports
NEUTRAL
424B5
4/10
Sempra filed a preliminary prospectus supplement for an offering of Floating Rate Notes due 2028, with the aggregate pri
Jun 4, 2026
NEUTRAL
8-K
3/10
Southern California Gas Company (an indirect subsidiary of Sempra) closed the public offering of $650 million aggregate
May 15, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
5 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 1 mixed, 3 neutral. Avg impact: 4.2/10.
NEUTRAL
424B5
4/10
Sempra filed a preliminary prospectus supplement for an offering of Floating Rate Notes due 2028, wi
Jun 4, 2026
NEUTRAL
8-K
3/10
Southern California Gas Company (an indirect subsidiary of Sempra) closed the public offering of $65
May 15, 2026
NEUTRAL
144
2/10
Sempra officer Diana L. Day filed a Form 144 to sell 3,300 shares of common stock with an estimated
May 14, 2026
MIXED
8-K
5/10
Sempra reported Q1 2026 GAAP EPS of $1.58 (up from $1.39 YoY) and adjusted EPS of $1.51 (up from $1.
May 7, 2026
BULLISH
8-K
7/10
Sempra's subsidiary Oncor received regulatory approval for a rate increase in Texas, resulting in an
Apr 17, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 75% buy across 24 analysts — 6 strong buy, 12 buy, 6 hold, 0 sell, 0 strong sell. No current recommendation available.
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 12 | 6 | 0 | 0 | 75% | |
| May 1, 2026 | 6 | 12 | 6 | 0 | 0 | 75% | |
| Apr 1, 2026 | 6 | 11 | 6 | 0 | 0 | 74% | |
| Mar 1, 2026 | 5 | 11 | 7 | 0 | 0 | 70% | |
| Feb 1, 2026 | 5 | 10 | 7 | 0 | 0 | 68% | |
| Jan 1, 2026 | 5 | 10 | 7 | 0 | 0 | 68% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.